|
⚲
|
| Keyboard |
| Sarissa Capital Management LP
✚
|
|
|---|---|
| CRD # | 167244 |
| SEC # | 801-77926 |
| CIK # | 0001577524 |
| AUM | 298.3 M (2026-03-31) |
| Employees | 4 (75% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 203-302-2330 |
| Address | 500 West Putnam Avenue Greenwich, CT 06830 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (7/8/2026) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION Each Advisory Client’s Governing Documents contains a detailed description of the applicable Fund’s fee schedule. A brief summary of such fees is provided below. For a full discussion of all fees paid to Sarissa all Investors, clients and prospective investors and prospective clients should refer to the Governing Documents Sarissa, or the applicable GP, deducts fees from each Fund’s assets. Investors do not have the ability to choose to be billed directly for fees incurred. An asset-based fee (the “Asset-Based Fee”) is payable to Sarissa by the Master Fund, Catapult Fund, Hawkeye Fund and ISP Fund quarterly in advance, on the first day of each calendar quarter. In addition, each of the Funds have issued a special interest that entitles the strategic investor to receive distributions calculated in the same manner, and payable at the same times, as the Asset-Based Fee (each such interest, an “Asset-Based Special Allocation Interest”). The total annual amount borne by an Investor in respect of the Asset-Based Fee and the Asset-Based Special Allocation Interest will be equal to 1.00%-1.75% (depending on the class of interests or shares and other factors set out in the applicable Fund’s Governing Documents) of the net value of the Investor’s account balance or series of shares, as applicable. The Asset-Based Fee will be prorated for partial periods. Investors in the Domestic Feeder and Offshore Feeder will bear only a single level of Asset-Based Fees and Asset-Based Special Allocation Interests. The Asset-Based Fee and Asset-Based Special Allocation Interests with respect to the Domestic Feeder and the Offshore Feeder will be calculated at the level of the Domestic Feeder and Offshore Feeder and applied against their respective Master Fund’s capital accounts corresponding to the interests/shares with respect to which the Asset-Based Fee and such distributions are calculated. Each of the Funds also bear an annual performance-based allocation (the “Incentive Allocation”). In addition, each of the Funds have issued a special interest that entitles the strategic investor to receive allocations calculated in the same manner as the Incentive Allocation (each such interest, a “Performance- Based Special Allocation Interest” and, together with the Asset-Based Special Allocation Interests, the “Special Allocation Interests”). The total amount borne by an Investor in respect of the Incentive Allocation and the Performance-Based Special Allocation Interest will be equal to 10%-20% (depending on the class of interests or shares) of net realized and unrealized appreciation otherwise allocable to such Investor’s account balance or series of shares, as applicable. The Incentive Allocation is generally calculated as of the last day of each fiscal year. The Incentive Allocation is subject to a high water-mark provision, such that generally an Investor will not be subject to an Incentive Allocation until any net loss previously allocated to such Investor’s account balance or series of shares, as applicable, has been offset by subsequent net profits. Investors in the Domestic Feeder and Offshore Feeder will bear only a single level of Incentive Allocation and allocations with respect to the Performance-Based Special Allocation Interests. The Incentive Allocation and allocations with respect to the Performance-Based Special Allocation Interests will be calculated at the Offshore Feeder level and allocated at the Master Fund level. The Asset-Based Fee, Asset-Based Special Allocation Interests, Incentive Allocation and Performance- Based Special Allocation Interests will be adjusted for capital contributions and withdrawals/redemptions made during the applicable period. The Asset-Based Fee, Asset-Based Special Allocation Interests, Incentive Allocation and Performance- Based Special Allocation Interests are calculated at different rates depending on the particular class of interests or shares, as applicable, in which Investors in the Funds subscribe. The Funds may reduce, waive, or calculate differently the Asset-Based Fee and/or Incentive Allocation with respect to any Investor, through a side letter, the PPM, or otherwise, including Investors that are affiliates or employees of Sarissa, entities established for their benefit, charitable organizations sponsored or managed by such persons and including, in particular, during any wind down of the applicable Fund’s business. In addition to Asset-Based Fee and Incentive Allocation payable to Sarissa or the applicable GP, the Funds will bear their own operating and other expenses, which include, without limitation: investment and trading- related expenses of the Funds (these are expenses directly related to the investment program and include, for instance, brokerage commissions, ticket charges, expenses related to short sales, clearing, and settlement charges, custodial fees, interest expenses, financing charges, initial and variation margin, broken deal expenses and other transactional charges, fees or costs, consulting, advisory, investment banking, valuation and any other professional fees or compensation relating to particular investments or contemplated investments, appraisal fees and expenses, investment-related travel and lodging expenses, and research- related expenses, including news and quotation equipment and services, market data services, fees to third- party providers of research, portfolio risk management services, market information systems and/or computer software and information expenses); costs relating to communications with investors; accounting, audit and tax preparation and compliance expenses (including preparation costs of financial statements, tax returns, reports to the Investors); printing and mailing costs, fees of pricing services, valuation firms and financial modeling services; expenses relating to activist campaigns, such as proxy contests, solicitations ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (7/8/2026) [Brochure] |
|---|
ITEM 7 – TYPES OF CLIENTS Sarissa provides investment advisory services to the Funds. Each Investor in the Funds must meet the eligibility provisions outlined in the applicable Fund’s Governing Documents. Generally, the minimum initial capital commitment in each Fund is $10,000,000, and the minimum additional capital commitment is $500,000. These minimum commitment amounts are subject to reduction or waiver at the sole discretion of the GPs, but in no event will the minimum initial capital commitment be less than the statutory minimum required by Cayman Islands law for the Offshore Feeder (currently $100,000). |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Theravance Inc | 49.7 | ||
| Ironwood Pharmaceuticals Inc | 32.3 | ||
| Amarin Corp PLC UK | 24.2 | ||
| Neurocrine Biosciences Inc | 15.4 | ||
| Cytokinetics Inc | 15.1 | ||
| Lantheus Holdings Inc | 12.7 | ||
| Biohaven Ltd | 4.8 | ||
| Regeneron Pharmaceuticals Inc | 3.2 | ||
| Vor Biopharma Inc | 0.5 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | ISP Fund LP | 2021-03-31 | 79.5 M | |
| HF | Sarissa Capital Master Fund II LP | [2021-03-31] | 9.0 M | 9.8 M |
| Filed 2024-05-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sarissa Capital Athena Fund Ltd | 2020-03-30 | 59.4 M | |
| HF | Sarissa Capital Hawkeye Fund LP | 2020-03-30 | 22.2 M | |
| HF | Sarissa Capital Catapult Fund LLC | [2018-03-29] | 132.3 M | 130.7 M |
| Filed 2025-11-12 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sarissa Capital Domestic Fund LP | [2013-04-02] | 351.7 M | 321.5 M |
| Filed 2025-07-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sarissa Capital Offshore Master Fund LP | [2013-04-02] | 65.9 M | |
| Filed 2025-07-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 6 | 298.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 6 | 298.3 |
| By Discretionary | ||
| Discretionary | 6 | 298.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 6 | 298.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 39.6 | |
| United States Persons | 258.8 | |
| Total | 6 | 298.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Geoff Ruddick | Director | 256 | 66 | |
| Jonathan Roney | Director | 99 | 18 | |
| Alexander Denner | Director, Executive Officer | 6 | 2 | |
| Sarissa Capital Fund GP LP | Director | 1 | 1 | |
| Mark Dipaolo | Executive Officer | 1 | 1 | |
| Patrice Bonfiglio | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001577524] | |
| 3 | [0001577524] | |
| 4 | [0001577524] | |
| SC 13D | [0001577524] | |
| SC 13G | [0001577524] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.6B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2025-12-15 | Grant | 4,178 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2025-06-13 | Grant | 24,193 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2025-06-10 | Grant | 45,000 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2025-04-02 | Grant | 10,416 | $0.00 | |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2025-03-06 | Sell | 1,196,746 | $17.52 | 20,966,990 |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2025-03-05 | Sell | 270,374 | $17.63 | 4,766,694 |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2025-03-04 | Sell | 151,175 | $17.63 | 2,665,215 |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-12-16 | Grant | 4,249 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-09-16 | Grant | 3,282 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-06-18 | Grant | 24,311 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-06-15 | Grant | 2,572 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-03-15 | Grant | 1,662 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2023-12-15 | Grant | 1,347 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2023-09-15 | Grant | 1,798 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2023-06-20 | Grant | 22,350 | $0.00 | |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2023-06-15 | Buy | 62,000 | $13.13 | 814,060 |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2023-06-15 | Grant | 1,359 | $0.00 | |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2023-06-06 | Buy | 8,000 | $13.05 | 104,400 |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2023-06-05 | Buy | 7,000 | $13.04 | 91,280 |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2023-05-30 | Buy | 120,000 | $13.01 | 1,561,200 |
| showing 20 of 57 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Panoramic Capital LLC
✚
|
CA | 299.6 M |
|
Greenhaven Road Investment Management LP
✚
|
CT | 299.5 M |
|
Polpo Capital Management LLC
✚
|
299.5 M | |
|
MQS Management LLC
✚
|
NY | 299.4 M |
|
Osmosis Investment Management US LLC
✚
|
298.9 M | |
|
GS Gamma Advisors LLC
✚
|
NY | 298.6 M |
|
Mercator Management USA LP
✚
|
NJ | 297.6 M |
|
Ananym Capital Management LP
✚
|
NY | 297.6 M |
|
High Trail Capital LP
✚
|
NJ | 296.9 M |
|
ADW Capital Management LLC
✚
|
296.8 M |